Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma PatientsJuly 28, 2025
KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025April 15, 2025
Study Validates Effectiveness of KYAN Tech’s Platform for Combination Therapy Prediction and Target Discovery in SarcomaMarch 25, 2025
Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testingMarch 14, 2025
KYAN Technologies to Present Lymphoma Immunotherapy Response Data for Predictive Platform at 2025 AACR IO ConferenceFebruary 20, 2025
KYAN Technologies’ platform used to find drug combination and potential biomarker in radio-resistant cancer studyJanuary 24, 2025
KYAN Technologies to Present Predictive Cancer Response Test Immunotherapy Data at the 66th ASH Annual MeetingDecember 5, 2024
KYAN Technologies to Present AML Concordance Data at the 65th ASH Annual Meeting and ExpositionDecember 4, 2024
KYAN Technologies’ cancer response prediction platform shows high accuracy for leukemia in clinical study publicationDecember 2, 2024
